Supporting your INOmax® (nitric oxide) gas, for inhalation, reimbursement needs

test alt test alt

INOmax reimbursement assessment and assistance

As an INOmax customer, your Director of National Accounts (DNA) can offer ongoing support to help you navigate the on-label INOmax reimbursement process. Your DNA can assist you through the following:

  • Ongoing INOmax reimbursement support

  • Assisting your finance and clinical teams with identifying current reimbursement strategies for INOmax

  • Providing Mallinckrodt’s understanding and perspective on local, regional, and national reimbursement trends

  • You are ultimately responsible for determining the appropriate reimbursement strategies and billing codes.

    • Have additional questions?

    Contact a representative

    INDICATION

    INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

    IMPORTANT SAFETY INFORMATION

    • INOmax® (nitric oxide) gas, for inhalation, is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
    • Abrupt discontinuation of INOmax may lead to increasing pulmonary artery pressure and worsening oxygenation.
    • Methemoglobinemia and NO2 levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOmax on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.
    • In patients with pre-existing left ventricular dysfunction, INOmax may increase pulmonary capillary wedge pressure leading to pulmonary edema.
    • Monitor for PaO2, inspired NO2, and methemoglobin during INOmax administration.
    • INOmax must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System.

    Please see Full Prescribing Information.

    Live help is available 24/7/365

    Call 877-566-9466

    Quick Links

    INOmax DSIR® Plus Virtual Training Simulator Resource Library FLEXtraNet® Log-in INOmax DSIR® Plus Operation Manual INOmax DSIR® Plus MRI Operation Manual

    Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.

    This website may identify third-party organizations and provide links to third-party websites or other third-party information (third-party content). The third-party content is meant for informational purposes only, is not endorsed by or under the control of Mallinckrodt, and is not meant to replace a physician’s medical advice. Mallinckrodt has no responsibility or liability for and makes no representations or warranties whatsoever about any third-party content. All trademarks, service marks, and logos appearing on this website are the property of their respective owners. Any rights not expressly granted herein are reserved.

    © 2024 Mallinckrodt. All rights reserved. US-2400124 03/24

    By viewing this site you agree to our Terms of Use. The product information provided in this site is intended only for residents of the United States. The product discussed herein may have different product labeling in different countries.

    INDICATION

    INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

    INDICATION

    INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

    IMPORTANT SAFETY INFORMATION

    • INOmax® (nitric oxide) gas, for inhalation, is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
    • Abrupt discontinuation of INOmax may lead to increasing pulmonary artery pressure and worsening oxygenation.
    • Methemoglobinemia and NO2 levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOmax on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.
    • In patients with pre-existing left ventricular dysfunction, INOmax may increase pulmonary capillary wedge pressure leading to pulmonary edema.
    • Monitor for PaO2, inspired NO2, and methemoglobin during INOmax administration.
    • INOmax must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System.

    Please see Full Prescribing Information.